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Purpose: NAD(P)H:Quinone Oxidoreductase 1 (NQO1) C609T missense variant 
(NQO1*2) and 29 basepair (bp)-insertion/deletion (I29/D) polymorphism of the 
NRH:Quinone Oxidoreductase 2 (NQO2) gene promoter have been proposed as 
predictive and prognostic factors for cancer development and progression. The 
purpose of this study is to investigate the relationship between NQO1/NQO2 gen-
otype and clinico-pathological features of papillary thyroid microcarcinoma 
(PTMC). Materials and Methods: Genomic DNA was isolated from 243 pa-
tients; and clinical data were retrospectively analyzed. NQO1*2 and tri-allelic 
polymorphism of NQO2 were investigated by polymerase chain reaction (PCR) 
and restriction fragment length polymorphism (RFLP) analysis. Results: PTMC 
with NQO1*2 frequently exhibited extra-thyroidal extension as compared to 
PTMC with wild-type NQO1 (p=0.039). There was a significant relationship be-
tween I29/I29 homozygosity of NQO2 and lymph node metastasis (p=0.042). 
Multivariate analysis showed that the I29/I29 genotype was associated with an in-
creased risk of lymph node metastasis (OR, 2.24; 95% CI, 1.10-4.56; p=0.026). 
Conclusion: NQO1*2 and I29 allele of the NQO2 are associated with aggressive 
clinical phenotypes of PTMC, and the I29 allele represents a putative prognostic 
marker for PTMC.
Key Words:   NAD(P)H:Quinone Oxidoreductase 1, NRH:Quinone Oxidoreduc-
tase 2, thyroid neoplasm
INTRODUCTION
NAD(P)H:Quinone Oxidoreductase 1 (NQO1) and NRH:Quinone Oxidoreduc-
tase 2 (NQO2) have been reported to confer protection against oxidative stress and 
carcinogenesis.1-3 Homozygous deletion of NQO1 in mice results in reduced p53 
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the NQO1*2 polymorphism modified cancer risk and was 
significantly associated with the K-ras codon 12 mutation.18 
There is another presumptive evidence for a protective 
role of NQO1 and NQO2 in thyroid carcinogenesis; these 
proteins can stabilize and increase p53 levels. The presence 
of an inactivating mutation of p53 is relatively rare in dif-
ferentiated thyroid cancer, suggesting that alternative mech-
anisms, such as functional inactivation of p53, may be in-
volved in the initiation or progression of PTC.19 Decreased 
expression of NQO1 and NQO2 could represent one such 
mechanism of permissive carcinogenesis in PTC. 
In the present study, we investigated the frequency and 
clinical outcomes associated with the NQO1*2 polymor-
phism and the tri-allelic polymorphism of the NQO2 pro-
moter in nodular hyperplasia (NH) and papillary thyroid 
microcarcinoma (PTMC), in order to elucidate the geno-
type-phenotype relationship between these polymorphisms 
and clinico-pathological features of PTMC. 
MATERIALS AND METHODS
　　　
Patient selection and DNA preparation
This is a retrospective study of 243 patients who underwent 
thyroid surgery because of their incidentally discovered 
thyroid nodules between June, 2002, and December, 2006, 
at the Center for Endocrine Surgery, Chungnam National 
University Hospital and St. Mary’s Hospital, The Catholic 
University of Korea. Under the American Thyroid Associa-
tion guidelines, US-guided fine needle aspiration biopsy 
(FNAB) was performed for nodules smaller than 1 cm which 
showed suspicious ultrasound findings. On the basis of 
FNAB cytological analysis, patient with malignant and in-
determinate or suspicious neoplasm underwent thyroid sur-
gery and final pathologic diagnosis was obtained. Genomic 
DNA from paraffin-embedded tissue was isolated using the 
QIAamp DNA Mini Kit (Qiagen, Chatsworth, CA, USA). 
The Institutional Review Boards of each university approved 
all of the study protocols. 
Pyrosequencing of BRAFV600E
Exon 15 of the BRAF gene was amplified from genomic 
DNA by PCR (5 μL reaction volume) and then sequenced 
by pyrosequencing, as previously described.20 In brief, DNA 
amplification was performed using the following primers: 
forward, 5’-ATGCTTGCTCTGATAGGAAA-3’, and re-
verse, 5’-ATTTTTGTGAATACTGGGGAA-3’. Amplified 
induction and decreased apoptosis; these knockout mice 
also exhibit an increased susceptibility to chemical-induced 
skin carcinogenesis.4 In NQO2-null mice, p53 is rapidly de-
graded and B-cell apoptosis is decreased, which suggests 
that NQO2 functions similarly to NQO1.5
Recent genetic studies have revealed that polymorphisms 
of NQO1 and NQO2 can alter enzymatic activity and can-
cer susceptibility. A well-characterized polymorphism of 
NQO1 is NQO1*2, a C609T missense variant (rs1800566, 
NP-000894:p.187P>S) that results in proline-187-serine 
(P187S) substitution of NQO1.6 NQO1 P187S is rapidly 
degraded through the ubiquitin proteosomal pathway, and 
NQO1*2 carriers have decreased NQO1 activity.7 NQO1*2 
is also associated with an increased risk of developing can-
cer and poor prognosis in leukemia and breast cancer pa-
tients.8,9 The most widely studied NQO2 polymorphism is a 
29 basepair (bp)-insertion/deletion (I29/D) polymorphism 
of the NQO2 gene promoter.10 This tri-allelic polymor-
phism consists of a 29 bp-insertion (I29), a 29 bp-deletion 
(D), and a 16 bp-insertion (I16). Recent data from genetic 
studies suggest that Sp3, a repressor of NQO2 gene expres-
sion, binds to I29 in the NQO2 promoter, resulting in de-
creased gene expression and enzymatic activity of NQO2.11 
Consistent with this observation, it has been suggested that 
the I29 allele may be a candidate cancer susceptible gene in 
breast cancer.12
Papillary thyroid cancer (PTC) is the most common endo-
crine cancers, andthe incidence of PTC has been increasing 
over the last decade.13 Well-characterized risk factors for 
PTC are radiation exposure and iodine,14 both of which can 
generate reactive oxygen species (ROS) that induce oxida-
tive stress and directly damage the DNA in follicular cells.15 
Indeed, oxidative DNA damage increases the spontaneous 
mutation rate (SMR) in mouse follicular cells.16 These results 
suggest that oxidative stress induced by certain carcinogens 
may be a causative factor in the initiation or progression of 
PTC, and enzymes that serve to link antioxidant systems, 
such as NQO1 and NQO2, might have a protective role 
against thyroid carcinogenesis. 
Studies into a genetic predisposition to thyroid cancer have 
suggested that forkhead box E1 and NK2 homeobox 1 are 
potential susceptibility loci in thyroid cancer;17 however, sim-
ilar studies to define susceptible genes for oxidative stress 
have not been successful. Furthermore, it is not known 
whether there is a relationship between oncogenic BRAFV600E 
and susceptibility genes for oxidative stress, as has been 
shown for other cancers. For example, in colorectal cancer, 
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Abcam plc, Cambridge, UK) primary antibody for 60 min at 
room temperature, after which they were treated sequential-
ly with biotinylated anti-mouse immunoglobulin for 30 min, 
peroxidase-labeled streptavidin for 30 min, and diamino-
benzidine in the presence of hydrogen peroxide. As a con-
trol, samples were incubated with PBS instead of primary 
antibody. No positive staining was observed in the control 
samples. Tissue sections of colon and breast carcinoma 
were also analyzed as positive controls. 
Statistical analysis
Hardy-Weinberg equilibrium and group comparisons of cat-
egorical variables were examined by the chi-square test or 
linear by linear association. Comparisons of means were 
evaluated with the independent samples t-test. Multivariate 
logistic regression analysis was performed to assess the as-
sociation of NQO1*2 with extra-thyroidal extension and 
the I29/I29 genotype with lymph node metastasis. Confi-
dence intervals (CIs) were computed by standard methods. 
All reported p-values are two sided and all analyses were 
performed using SPSS Versions 18.0 for Windows (SPSS 





Increased expression of NQO1 has frequently been docu-
mented in developing tumors, which suggests that NQO1 
participates in cellular defense mechanisms that protect 
against carcinogenesis.23 To validate these previous results 
in thyroid carcinoma, normal thyroid, NH and PTMC tis-
sues were subjected to immunohistochemistry using an an-
ti-NQO1 antibody. As shown in Fig. 1A, NQO1 was not 
readily detected in normal thyroid follicles. However, focal 
expression of NQO1 was observed in normal follicular 
cells and NH, particularly in the apical areas of follicular 
cells where relatively large amounts of H2O2 are generated 
for the synthesis of thyroid hormone (Fig. 1B and C). These 
results suggested that oxidative stress induces NQO1 ex-
pression in follicular cells. Diffuse cytoplasmic staining was 
readily observed in the PTMC harboring wild type NQO1 
(Fig. 1D and E), although in that of patients carrying an 
NQO1*2 polymorphism, the intensity of NQO1-positive 
signals was reduced (Fig. 1F). It is apparent that the expres-
sion of wild type NQO1 levels increased in cancer cells as 
compared to normal follicular cells, perhaps due to increased 
products were immobilized on magnetic beads, and then the 
bead/DNA complexes were subjected to pyrosequencing 
with the forward primer 5’-GGTGATTTTGGTCTAGC 
TAC-3’. Final single-stranded DNA templates were trans-
ported into a PSQ HS 96 A pyrosequencer system (Biotage, 
Uppsala, Sweden).
Detection of the C609T (P187S) polymorphism 
(rs1800566) of NQO1 
The substitution of C to T in exon 3 of NQO1 was detected 
by PCR-restriction fragment length polymorphism (RFLP) 
analysis using HinfI, as previously describ-ed.21 Briefly, ge-
nomic DNA was amplified in a 5 μL reaction volume by 
PCR using the following primers: forward, 5’-AGTG-
GCATTCTGCATTTCTGTG-3’, and reverse, 5’-GATG-
GACTTGCCCAAGTGATG-3’. Following restriction en-
zyme digestion by HinfI, wild-type NQO1 (NQO1 CC) 
appeared as two bands of 189 bp and 85 bp. Homozygous 
NQO1*2 (NQO1 TT) appeared as three bands (151 bp, 85 
bp and 37 bp), and heterozygous NQO1*2 (NQO1 CT) ap-
peared as bands of all four sizes. 
Analysis of the I29/D polymorphism of the NQO2 gene 
promoter
The I29/D polymorphism was detected by PCR-RFLP anal-
ysis using the following primers: forward, 5’-CTGCCTG 
GAAGTCAGCAGGGTC-3’, and reverse, 5-CTCTTTAC 
GCAGCGCGCCTAC-3’.22 The theoretical molecular weight 
of the amplified I29 allele was 290 bp, while that of I16 was 
277 bp and D was 261 bp. Since agarose gel electrophore-
sis was insufficient to discriminate between I29 and I16, 
RFLP analysis was carried out using Ava I, which yielded 
250 bp and 40 bp I29 fragments. 
Immunohistochemistry of NQO1 and Nrf2
Immunohistochemistry in normal thyroid tissue, NH and 
PTMC was performed. Briefly, 4 µm thick tissue sections 
were heated at 60°C, deparaffinized in xylene, and then hy-
drated in a graded series of alcohol. Then, antigen retrieval 
was performed by microwaving the samples in citrate buf-
fer for 10 min. Endogenous peroxidase activity was inacti-
vated by incubation in a solution of 3% hydrogen peroxide 
for 10 min, and then nonspecific binding sites were blocked 
by incubation in 10% normal goat serum in phosphate-
buffered saline (PBS). Tissue sections were incubated with 
NQO1 (Cell Signaling Technology, Boston, MA, USA) or 
nuclear factor (erythroid-derived 2)-like 2 (NFE2L2 or Nrf2, 
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was 58.3% (28/48) and 56.8% (71/125) in PTMC. There 
was no significant difference in the frequency of NQO1*2 
polymorphism between the two groups. 
Frequency of the I29/D polymorphism in the NQO2 
gene promoter
Immunohistochemical analysis of NQO2 expression in NH 
and PTMC was not possible due to unavailability of anti-
NQO2 antibody. However, since NQO2 also functions in 
protecting cells against oxidative stress, we examined the 
frequency of the I29/D polymorphism of the NQO2 gene 
promoter in patients with PTMC. Seventy-three NH and 
170 PTMC were analyzed, and the results are summarized 
in Table 1. In NH, 54.8% (40/73) of the samples were ho-
mozygous for the I29 allele (I29/I29), 31.5% (23/73) were 
oxidative stress in these cells. Furthermore, patients with 
the NQO1*2 polymorphism appeared to be defective in ox-
idative stress-induced expression of NQO1. Taken together, 
it is highly likely that NQO1*2 is linked to cancer initiation 
or progression in PTMC. 
Frequency of the C609T (P187S) polymorphism of 
NQO1 in PTMC
To better understand the role of NQO1 in PTMC, we investi-
gated the frequency of the NQO1*2 polymorphism in PTMC. 
Of 173 patients (48 NH and 125 PTMC) selected for the 
analysis (Table 1), none of the samples was homozygous 
for the NQO1*2 allele; however, the minor allele frequen-
cies was 0.29, which was in Hardy-Weinberg equilibrium 







Fig. 1. Immunohistochemical staining of NQO1 in the normal thyroid and PTMC. (A) NQO1 was rarely detected in normal thyroid follicles. (B and C) Focal ex-
pression of NQO1 was observed in the apical areas of normal follicular cells (boxed area and arrows). (D and E) Diffuse intense cytoplasmic staining was 
observed in papillary thyroid cancer cells from same patient with wild-type NQO1. (F) NQO1 expression was barely detectable in a patient with heterozy-
gous NQO1*2 polymorphism. All results are representative images. NQO1, NAD(P)H:Quinone Oxidoreductase 1; PTMC, papillary thyroid microcarcinoma.
Table 1. Frequency of NQO1 and NQO2 Polymorphisms in Nodular Hyperplasia and Papillary Thyroid Microcarcinoma 
NQO1* NQO2†
C/C (%) C/T (%) p value I29/I29 (%) I29/D (%) D/D (%) p value
NH 20 (41.7) 28 (58.3)
0.855‡
40 (54.8) 23 (31.5) 10 (13.7)
0.767§
PTMC 54 (43.2) 71 (56.8) 88 (52.4) 56 (33.3) 24 (14.3)
NQO1, NAD(P)H:Quinone Oxidoreductase 1; NQO2, NRH:Quinone Oxidoreductase 2; NH, nodular hyperplasia; PTMC, papillary thyroid microcarcinoma.
C/C: wild type NQO1. C/T: heterozygote C609T missense variant of NQO1. I29: 29 basepair insertion polymorphism of NQO2. D: 29 basepair deletion poly-
morphism of NQO2. 
*The NQO1 polymorphisms of 25 cases of 73 NH and 45 cases of 170 PTMC were not able to be assessed.
†Two cases of PTMC showing the I29/I16 genotype were not included.
‡Pair-wise comparisons from the Pearson χ2 test.
§Comparisons of three or four groups using linear by linear association.
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ality, lymph node metastasis and the presence of BRAFV600E 
mutation were similar in the presence and absence of 
NQO1*2 polymorphism. The presence of extra-thyroidal 
extension, however, was more common in PTMCs harbor-
ing NQO1*2 as compared to wild-type NQO1 (p=0.039) 
(Table 2). Multivariate analysis of the relationship between 
NQO1*2 and extra-thyroidal extension was carried out, 
omitting capsular invasion and TNM stage, as these factors 
are closely related to extra-thyroidal extension of PTMC. 
The results revealed no clear relationship between NQO1*2 
and extra-thyroidal extension (odds ratio, 1.82; 95% CI, 
0.85-3.89; p=0.124) (Table 3). 
Clinical impact of I29/D polymorphisms in PTMC
Analysis of the I29/D polymorphism revealed that 43% of 
I29/D heterozygotes, and 13.7% (10/73) were homozygous 
for the D allele (D/D). The frequencies of these NQO2 gene 
promoter polymorphisms were similar to those of PTMC, in 
which 51.8% (88/170) of the samples were of the I29/I29 
genotype, 32.9% (56/170) were I29/D heterozygotes, and 
14.2% (24/170) were D/D homozygotes. The minor allele 
frequency was 0.30, which was in Hardy-Weinberg equilib-
rium (p=0.947). We identified two PTMC samples that were 
of the I29/I16 genotype, but these samples were excluded 
from the analysis because the frequency of this genotype 
was too low to determine clinical significance.
Clinical impact of NQO1*2 in PTMC
Clinico-pathological parameters such as age at diagnosis, 
gender, tumor size, capsular invasion, multifocality, bilater-
Table 2. Impact of NQO1*2 on Clinicopathological Parameters of Study Patients with PTMC
NQO1 polymorphism
p value
C/C  (n=54) C/T  (n=71)
Age (yrs, mean±SD) 45.3±8.1 46.6±9.1  0.387*
Gender (%) 0.076†
    Female 54 (100) 67 (94.4)
    Male 0 (0) 4 (5.6)
Size of tumor (%) 0.695†
    ≤0.5 cm 13 (24.1) 15 (21.1)
    >0.5 cm 41 (75.9) 56 (78.9)  
Tumor size (mm, mean±SD) 6.93±2.1 7.17±2.1  0.526*
Capsular invasion (%) 0.067†
    Yes 23 (42.6) 41 (57.7)
    No 31 (57.4) 30 (42.3)
Extra-thyroidal extension (%) 0.039†
    Yes 18 (33.3) 36 (50.7)
    No 36 (66.7) 35 (49.3)
Multifocality (%) 0.744†
    Yes 19 (35.2) 27 (38)
    No 35 (64.8) 44 (62)
Bilaterality (%) 0.916†
    Yes 14 (25.9) 19 (26.8)
    No 40 (74.1) 52 (73.2)
Lymph node metastasis (%) 0.549†
    Yes 17 (31.5) 26 (36.6)
    No 37 (68.5) 45 (63.4)
TNM Stage (%) 0.355†
    Stage 1 42 (77.8) 50 (70.4)
    Stage 3 12 (22.2) 21 (29.6)
BRAFV600E mutation (%) 0.054†
    Positive 36 (38.3) 58 (61.7)
    Negative 18 (58.1) 13 (41.9)
NQO1*2, The NAD(P)H:Quinone Oxidoreductase 1 (NQO1) C609T missense variant; NH, nodular hyperplasia; PTMC, papillary thyroid microcarcinoma; SD, 
standard deviation. 
*Independent samples t-test.
†Pair-wise comparisons from the Pearson χ2 test.
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(Table 4). Furthermore, multivariate analysis clearly showed 
a significant correlation between the I29 allele and lymph 
node metastasis (odds ratio, 2.24; 95% CI, 1.10-4.56; p= 
0.026) (Table 5). 
patients with the I29/I29 genotype experienced lymph node 
metastasis as compared to only 20% of patients with the D/D 
genotype. This association between I29 homozygosity and 
lymph node metastasis was statistically significant (p=0.042) 
Table 3. Multivariate Analyses of the Association of Extra-Thyroidal Extension with NQO1*2 in Patients with PTMC
OR 95% CI p value
Age (≥45 yrs) 1.14 0.54-2.40 0.740
Gender (male) 2.57   0.25-26.61 0.429
Tumor size (>0.5 cm) 1.79 0.69-4.63 0.228
Capsular invasion N.I.
Multifocality 1.22 0.35-4.27 0.754
Bilaterality 0.59 0.15-2.42 0.466
Lymph node metastasis 1.27 0.58-2.79 0.550
TNM stage N.I.
BRAFV600E mutation 1.53 0.63-3.73 0.349
NQO1*2 1.82 0.85-3.89 0.124
N.I., not included in the multivariate analysis for extra-thyroidal extension; CI, confidence interval; NQO2, NRH:Quinone Oxidoreductase 2; PTMC, papillary 
thyroid microcarcinoma; OR, odd ratio. 
Table 4. Impact of NQO2 Polymorphism on Clinicopathological Parameters of Study Patients with PTMC 
NQO2 polymorphism
p value
I29/I29 (n=88) I29/D (n=56) D/D (n=24)
Age (yrs, mean±SD) 45.8±8.8 46.9±8.1 50.3±8.6  0.074*
Gender (%) 0.119†
    Female 83 (94.3) 55 (98.2) 24 (100)
    Male 5 (5.7) 1 (1.8) 0 (0)
Tumor size (mm, mean±SD) 7.27±2.0 7.45±2.0 6.83±2.3  0.473*
Capsular invasion (%) 0.821†
    Yes 50 (56.8) 35 (62.5)  12 (50.0)
    No 38 (43.2) 21 (37.5)  12 (50.0)
Extra-thyroidal extension (%) 0.398†
    Yes 36 (40.9) 29 (51.8)  11 (45.8)
    No 52 (59.1) 27 (48.2)  13 (54.2)
Multifocality (%) 0.458†
    Yes 32 (36.4) 21 (37.5)  11 (45.8)
    No 56 (63.6) 35 (62.5)  13 (54.2)
Bilaterality (%) 0.140†
    Yes 20 (22.7) 16 (28.6)    9 (37.5)
    No 68 (77.3) 40 (71.4)  15 (62.5)
Lymph node metastasis (%) 0.042†
    Yes 38 (43.2) 16 (28.6)    6 (25.0)
    No 50 (56.8) 40 (71.4)  18 (75.0)
TNM stage (%) 0.696†
    Stage 1 64 (72.7) 38 (67.9)  17 (70.8)
    Stage 3 24 (27.3) 18 (32.1)    7 (29.2)
BRAFV600E mutation (%) 0.606†
    Positive 67 (54.5) 38 (30.9)  18 (14.6)
    Negative 21 (46.7) 18 (40.0)    6 (13.3)
NQO2, NRH:Quinone Oxidoreductase 2; PTMC, papillary thyroid microcarcinoma; SD, standard deviation; ANOVA, analysis of variance.
*One-way ANOVA test.
†Comparisons of three or four groups using linear by linear association. 
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analysis of the frequency of NQO2 promoter polymor-
phisms in PTMC and NH also revealed no significant dif-
ferences in the frequency of the I29/D polymorphisms. 
However, the specific function of the thyroid gland is to 
produce a large amount of H2O2 for thyroid hormone syn-
thesis; therefore, follicular cells are likely to be highly sus-
ceptible to oxidative damage and vulnerable to frequent 
mutagenesis, particularly if antioxidant systems in these 
cells are not properly functioning.27-29 Animal experiments 
have shown that epithelial cells around the follicular lumen 
exhibit an increased SMR in the thyroid gland.27 In the cur-
rent study, NQO1 expression was detected by immunohis-
tochemistry in normal follicular cells and NH, particularly in 
apical areas, suggesting that NQO1 is involved in the cellu-
lar response to physiological or pathological oxidative stress. 
Thus, NQO1*2 may represent a susceptibility polymor-
phism for various thyroid diseases accompanied by exces-
sive ROS production.30 Although we were unable to per-
form immunohistochemistry of NQO2, we presume that 
the function of NQO2 in the thyroid is most likely similar 
to that of NQO1. 
Immunohistochemistry of Nrf2
To investigate the different anti-oxidative response accord-
ing to the presence or absence of NQO1*2 and NQO2 I29, 
we performed immunohistochemical staining for Nrf2. Nrf2 
is a well-known transcription activator binding to antioxi-
dant response elements and can be a useful marker against 
oxidative stress.24 As shown in Fig. 2, PTMC harboring 
NQO1*2 and NQO2 I29 showed highest staining intensity 
of Nrf2, suggesting that the absence of NQO1 and NQO2 
might provoke strong oxidative response. 
DISCUSSION
In the present study, we examined the frequency of the 
NQO1*2 and I29/D polymorphisms of NQO1 and NQO2, 
respectively, in NH and PTMC. Although NQO1*2 has 
been suggested to be a susceptibility polymorphism in lung 
cancer, leukemia and urogenital malignancy,3,4,25,26 our ge-
netic analysis did not reveal an increase in the frequency of 





Fig. 2. Representative immunohistochemical staining of Nrf2. (A) Nrf2 was rarely detected in PTMC with wild type NQO1 and NQO2. (B and C) Moderate ex-
pression of Nrf2 was observed in PTMC with NQO1*2 (B) or NQO2 I29/I29 (C). (D) Strong and diffuse intense staining was observed in PTMC with NQO1*2 
and NQO2 I29/ I29. PTMC, papillary thyroid microcarcinoma; NQO1, NAD(P)H:Quinone Oxidoreductase 1; NQO2, NRH:Quinone Oxidoreductase 2.
Table 5. Multivariate Analyses of the Association of Lymph Node Metastasis with I29/I29 Alleles in Patients with PTMC 
OR 95% CI p value
Age (≥45 yrs) 0.67 0.33-1.33 0.247
Gender (male) 0.66 0.10-4.40 0.667
Tumor size (>0.5 cm) 1.07 0.42-2.72 0.880
Capsular invasion 2.49 0.83-7.44 0.102
Extra-thyroidal extension 0.64 0.22-1.87 0.418
Multifocality 0.18 0.04-0.88 0.034
BRAFV600E mutation 1.07 0.49-2.32 0.872
I29/I29 2.24 1.10-4.56 0.026
PTMC, papillary thyroid microcarcinoma; CI, confidence interval; OR, odd ratio. 
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showed that patients with the I29/I29 genotype were at 
higher risk of lymph node metastasis. In fact, previous stud-
ies reported that the NQO1*2 is a prognostic marker for leu-
kemia, breast and lung cancers to predict poor patients’ out-
come and resistance to conventional therapy.8,9,33 However, 
the prognostic impact of the I29/I29 genotype has not been 
extensively investigated, although the inactivation of NQO1 
and NQO2 is strongly related to the multiplicity of skin tu-
mors in murine models.34 The mechanism by which ROS 
can affect tumor behaviors is the genotoxicity of ROS such 
as ROS-mediated DNA damage, ineffective DNA repair 
mechanisms or genomic instability.35,36 The other important 
ROS effect on tumor cells is mitochondrial DNA alterations 
because mitochondrial DNA has no histone protection.37 Epi-
genetic alteration such as aberrant CpG island hypermethyl-
ation is also related to ROS-mediated carcinogenesis.38,39 To 
the best of our knowledge, we could not define the exact pro-
tective mechanism of NQO1 and NQO2 against carcinogen-
esis. However, we suspect that excessive accumulation of 
ROS is able to promote cancer initiation, promotion and pro-
gression, and that the defect of cellular defense system such 
as NQO1*2 and the I29/I29 genotype may aggravate genetic 
and epigenetic alteration in human carcinogenesis. 
Taken together, these clinical features associated with 
NQO1*2 and I29 alleles in PTMC suggested that NQO2 
polymorphisms may significantly affect enzymatic activi-
ties and attenuate the preventive functions of NQO2 against 
cancer progression. Thus, I29 allele represents a putative 
prognostic indicator for PTMC. 
Analysis of frequency and clinical impact of NQO1*2 and 
I29 allele polymorphisms of NQO1 and NQO2, respective-
ly, revealed that patients who carry the NQO1*2 polymor-
phism might be predisposed to extra-thyroidal extension of 
PTMC, while the I29 allele of NQO2 was strongly associ-
ated with lymph node metastasis. Future studies on the bio-
logical role and the prognostic indicator of these NQO1 and 
NQO2 polymorphisms will contribute to a better under-
standing of the role of oxidative stress defense mechanisms 
in the development and progression of PTMC.
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Anti-oxidant enzymes such as thioredoxin reductase and 
glutathione peroxidase 3 (GPX3) have been proposed as pro-
tective mechanisms against H2O2-induced oxidative stress 
and are potentially involved in the regulation of thyroid hor-
mone synthesis. There is a clear association between GPX3 
gene polymorphism and the occurrence of differentiated thy-
roid cancer, which is consistent with an important role in an-
tioxidant systems of protecting cells against DNA mutation 
and carcinogenesis.31 To definitively confirm the protective 
effect of NQO1 and NQO2 against mutagenesis, such as in 
BRAFV600E-induced carcinoma, a more comprehensive anal-
ysis of other genes that are coordinately induced with NQO1, 
such as glutathione S-transferase, UDP-glucuronyl transfer-
ase, and γ-glutamylcysteine synthase, should also be per-
formed. Also, it is important to note that the current study did 
not analyze other known polymorphisms of NQO2, such as 
rs2071002 (+237A>C), which has recently been identified 
as a risk allele in breast cancer.12 Emerging polymorphisms 
should be included in future studies of the roles of NQO1 
and NQO2 in defending against ROS-induced mutagenesis. 
However, in our immunohistochemistry study for Nrf2, the 
presence of NQO1*2 and NQO2 I29 strongly induced Nrf2 
expression, suggesting that dysfunction of NQO1 and 
NQO2 might be able to provoke higher oxidative response 
in tumor cells. 
In general, most of studies of NQO1 and NQO2 poly-
morphisms have used genomic DNA isolated from blood. 
In the current study, however, we used DNA from tumor 
because this study was designed retrospectively. Activating 
mutations such as H-RASV16 or BRAFV600E induces genomic 
instability through constitutive activation of mitogen-acti-
vated protein kinase, a mechanism that may induce addi-
tional somatic mutation.32 To determine whether NQO1 or 
NQO2 polymorphisms were due to genomic instability, 
NQO1 and NQO2 polymorphisms in genomic DNA from 
tumor and contralateral normal tissue from the same patient 
were analyzed in 45 PTMCs. However, there was no differ-
ence in polymorphism status between tumor tissue and con-
tralateral normal tissue in any of the samples (data not 
shown), indicating that NQO1 and NQO2 polymorphisms 
in these tumors were not due to genomic instability. 
In this study, PTMC with NQO1*2 polymorphism was 
frequently accompanied by extra-thyroidal extension, al-
though multivariate analysis did not support a strong rela-
tionship. Perhaps, the most intriguing result of the current 
study was that the I29 allele exhibited a marked association 
with lymph node metastasis. Multivariate analysis clearly 
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